Targeted Combo Fails in EGFR-Mutant NSCLC

(MedPage Today) -- Adding a VEGF inhibitor to osimertinib (Tagrisso) failed to improve survival outcomes in previously treated patients with EGFR T790M-positive non-small cell lung cancer (NSCLC), a small randomized study from Japan showed.
For...